Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis
Life Science Alliance · 2023-10 · 6 (10) · e202302055
DOI: 10.26508/lsa.202302055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 27.07.2023. Verfasst von Lukas A Heger und 9 weiteren Autor:innen. Beteiligte Einrichtung: Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA. Hauptthemen laut MEDLINE: Heart Failure, Arthritis. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, HHS | NIH | National Heart, Lung, and Blood Institute, Deutsche Forschungsgemeinschaft.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Rheumatoid arthritis is a prototypic inflammatory condition with affected patients being at greater risk of incident heart failure (HF). Targeting innate immune cell function in the pathogenesis of HF bears the potential to guide the development of future therapies. A collagen-induced arthritis (CIA) model in DBA/1 J mice was used to generate arthritis. Mice with CIA developed concentric hypertrophic myocardial remodeling, left ventricular (LV) diastolic dysfunction, and HF with elevated plasma B-type natriuretic peptide levels but preserved LV ejection fraction. Key features of HF in CIA were increased infiltration of activated neutrophils, deposition of neutrophil extracellular traps in the myocardium, and increased tissue levels of the proinflammatory cytokine IL-1β. Specific inhibition of protein arginine deiminase 4 (PAD4) by an orally available inhibitor (JBI-589), administered after the onset of clinical arthritis, prevented HF with reduced neutrophil infiltration. We identify PAD4-mediated neutrophil activation and recruitment as the key thromboinflammatory pathway driving HF development in arthritis. Targeting PAD4 may be a viable therapeutic approach for the prevention of HF secondary to chronic inflammation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA.
- Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
- Departement of Cardiology and Angiology, University Hospital Freiburg Bad Krozingen, Freiburg, Germany.
- Center of Molecular and Vascular Biology, Department of Cardiovascular Science, KU Leuven, Leuven, Belgium.
- Jubilant Therapeutics Inc., Bedminster, NJ, USA.
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Boston, MA, USA denisa.wagner@childrens.harvard.edu.
ORCID-Profile: Lukas A Heger, Nicolas Schommer, Stijn Van Bruggen, Long Chu, Denisa D Wagner
Förderung
- NHLBI NIH HHS
- HHS | NIH | National Heart, Lung, and Blood Institute
- Deutsche Forschungsgemeinschaft
- German Research Foundation
- Society for Thrombosis and Haemostasis Research e.V.
Zitieren
APA
Heger, L. A., Schommer, N., Fukui, S., Van Bruggen, S., Sheehy, C. E., Chu, L., Rajagopal, S., Sivanandhan, D., Ewenstein, B., & Wagner, D. D. (2023). Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis. Life Science Alliance, 6(10), e202302055. https://doi.org/10.26508/lsa.202302055
Vancouver
Heger LA, Schommer N, Fukui S, Van Bruggen S, Sheehy CE, Chu L, et al. Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis. Life Science Alliance. 2023;6(10):e202302055. doi:10.26508/lsa.202302055
BibTeX
@article{Heger2023,
author = {Heger, Lukas A and Schommer, Nicolas and Fukui, Shoichi and Van Bruggen, Stijn and Sheehy, Casey E and Chu, Long and Rajagopal, Sridharan and Sivanandhan, Dhanalakshmi and Ewenstein, Bruce and Wagner, Denisa D},
title = {Inhibition of protein arginine deiminase 4 prevents inflammation-mediated heart failure in arthritis},
journal = {Life Science Alliance},
year = {2023},
volume = {6},
number = {10},
pages = {e202302055},
doi = {10.26508/lsa.202302055}
}
EUVIMED